 |
|
|
| |
LIK066 (LICOGLIFLOZIN), AN SGLT1/2 INHIBITOR, IMPROVES MARKERS OF HEPATIC AND METABOLIC HEALTH IN PATIENTS WITH
NONALCOHOLIC FATTY LIVER DISEASE: FULL STUDY ANALYSIS OF A 12-WEEK, RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2A STUDY
|
| |
| |
AASLD 2020 Nov 11-16
Reported by Jules Levin
Stephen A. Harrison1, Eric Sicard2, Frederico Perez Manghi3, William B. Smith4 , Diana Alpenidze5, Diego Aizenberg6, Naomi Klarenbeek7, Chi-Ye Chen8, Eli Zuckerman9, Eric Ravussin10, Phunchai Charatcharoenwitthaya11, Pin-Nan Cheng12 ,
Helena Katchman13, Samuel Klein14, Ziv Ben-Ari15, Anisha Mendonza16, Yiming Zhang17, Miljen Martic18, Shenglin Ma16, Sandra Tanner18, Alok Pachori16, YanLing He16 and Chinweike Ukomadu16
1Pinnacle Clinical Research, San Antonio, Texas, USA; 2Altasciences Algorithme Pharma, Quebec, Canada; 3CINME, Buenos Aires, Argentina; 4New Orleans Center for Clinical Research, Knoxville, USA; 5City Out-patient Clinic #117, St. Petersburg, Russia; 6Centro Medico Viamonte, Buenos Aires, Argentina;
7Center for Human Drug Research, Leiden, Netherlands; 8Chiayi Christian Hospital, Taiwan; 9Carmel Medical Center, Haifa, Israel; 10Pennington Biomedical Research Center; Baton Rouge, USA; 11Siriraj Hospital, Bangkok, Thailand; 12National Cheng Kung University Hospital, Taiwan; 13Tel Aviv Sourasky Medical Center,
Tel Aviv, Israel; 14Washington University School of Medicine, St. Louis, USA; 15Sheba Medical Center, Ramat Gan, Israel; 16Novartis Institutes For BioMedical Research, Cambridge, USA; 17Novartis Institutes For BioMedical Research, East Hanover, USA; 18Novartis Institutes For BioMedical Research, Basel, Switzerland
First-in-Human Study of Dual Inhibitor Licogliflozin Showed Significant Weight Loss in Obese Patients
https://www.ajmc.com/view/firstinhuman-study-of-dual-inhibitor-licogliflozin-showed-significant-weight-loss-in-obese-patients
|
| |
|
|
|
|
|
